medigraphic.com
ISSN 2007-6509 (Impreso)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2020, Número 1

<< Anterior Siguiente >>

Rev Mex Med Transfus 2020; 13 (1)


Evaluación y manejo de la refractariedad plaquetaria: una propuesta

Calderón GA, Graciano VN

Idioma: Español
Referencias bibliográficas: 42
Paginas: 7-14
Archivo PDF: 175.56 Kb.


RESUMEN

Introducción: La refractariedad plaquetaria se define como un incremento plaquetario postransfusión menor al esperado, se presenta en 27% de los pacientes a los que se les realiza transfusión plaquetaria, lo que constituye una limitación a la hora de transfundir un paciente con esta condición. Objetivo: Proponer un enfoque práctico para la evaluación y el manejo de los pacientes con refractariedad plaquetaria. Se sugiere un algoritmo para su tratamiento. Material y métodos: Se realizó una búsqueda de referencias bibliográficas actualizadas sobre el tema de interés en la base de datos MEDLINE, a través del motor de búsqueda PubMed. Conclusiones: El manejo de la refractariedad plaquetaria inicia con la prevención de la sensibilización. A la fecha no existe un método para diagnosticar de forma precisa la refractariedad de origen no inmune, y en muchas ocasiones puede coexistir con algún grado de refractariedad inmune.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fasano R, Josephson C. Platelet transfusion goals in oncology patients. Hematology. 2015; 2015: 462-470. doi: 10.1182/asheducation-2015.1.462.

  2. Gibson BE, Todd A, Roberts I et al. Transfusion guidelines for neonates and older children. Br J Haematol. 2004; 124 (4): 433-453. doi: 10.1111/j.1365-2141.2004.04815.x.

  3. Wandt H, Ehninger G, Gallmeier W. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist. 2001; 6 (5): 446-450. doi: 10.1634/theoncologist.6-5-446.

  4. Phekoo K, Hambley H, Schey S, Win N, Carr R, Murphy M. Audit of practice in platelet refractoriness. Vox Sanguinis. 1997; 73 (2): 81-86. doi: 10.1046/j.1423-0410.1997.7320081.x. 

  5. The Trial to Reduce Alloimmunization To Platelets Study Group. Leukocyte reduction and utraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337 (26): 1861-1869.

  6. Slicther S, Davis K, Enright H, Braine H, Gernshimer T, Kao K et al. Factors affecting post-transfusion platelets increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005; 105 (10): 4106-4114. doi: 10.1182/blood-2003-08-2724.

  7. Quillen K. Diagnosis and management of platelet alloimmunization. Column Ask the Hematologist. Hematology. 2013; 10 (6): 1023.

  8. Daly A, Hasegawa W, Lipton J, Messner H, Kiss T. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and veno-occlusive disease of the liver. Transfus Apher Sci. 2002; 27 (1): 3-12.

  9. McCullough J. Overview of platelet transfusion. Semin Hematol. 2010; 47 (3): 235-242. doi: 10.1053/j.seminhematol.2010.04.001.

  10. Novotny V. Prevention and management of platelet transfusion refractoriness. Vox Sang. 1999; 76 (1): 1-13.

  11. Schiffer C, Anderson K, Bennett C, Bernstein S, Elting L, Goldsmith M et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19 (5): 1519-1538.

  12. Pavensky K, Freedman J, Semple J. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012; 79 (4): 237-245. doi: 10.1111/j.1399-0039.2012.01852.x.

  13. Dzik S. How I do it: platelet support for refractory patients. Transfusion. 2007; 47 (3): 374-378. doi: 10.1111/j.1537-2995.2007.01126.x.

  14. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev. 2000; 14 (2): 180-196. doi: 10.1016/s0887-7963(00)80007-3.

  15. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008; 142 (3): 348-360. doi: 10.1111/j.1365-2141.2008.07189.x.

  16. Stanworth S, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015; 171 (3): 297-305. doi: 10.1111/bjh.13597.

  17. Schiffer C. State-of-the-art mini-review. Management of patients refractory to platelet transfusion. Leukemia. 2001; 15 (4): 683-685.

  18. Forest S, Hod E. Management of the platelet refractory patient. Hematol Oncol Clin N Am. 2016; 30 (3): 665-677. doi: 10.1016/j.hoc.2016.01.008.

  19. Valsami S, Dimitroulis D, Gialeraki A, Chimonidou M, Politou M. Current trends in platelet transfusions practice: the role of ABO-RhD and human leukocyte antigen incompatibility. Asian J Transfus Sci. 2015; 9 (2): 117-123. doi: 10.4103/0973-6247.162684.

  20. Kiefel V, König C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Platelet alloantibodies in transfused patients. Transfusion. 2001; 41 (6): 766-770. doi: 10.1046/j.1537-2995.2001.41060766.x.

  21. Panzer S, Auerbach L, Cechova E, Fischer G, Holesteiner A, Kitll E et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol. 1995; 90 (3): 655-660.

  22. Kurz M, Greinix H, Cker P, Kalhs P, Kno P, Mayr W et al. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol. 1996; 95 (3): 564-569. doi: 10.1046/j.1365-2141.1996.d01-1936.x.

  23. Dutcher J, Schiffer C, Aisner J, Wiernik P. Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood. 1981; 59 (5): 1007-1011.

  24. Seftel M, Growe G, Petraszko T, Barret B, Le A, Lee C et al. Universal leukorecution in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004; 103 (1): 333-339. doi: 10.1182/blood-2003-03-0940.

  25. Heddle N, Arnold D, Boye D, Webert K, Resz I, Dumont L. Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review. Transfusion. 2008; 48 (7): 1447-1458. doi: 10.1111/j.1537-2995.2008.01731.x.

  26. Vasallo R, Fung M, Rebulla P, Duquesnoy R, Saw C, Slichter S. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion. 2014; 54 (4): 1180-1191. doi: 10.1111/trf.12395.

  27. Rebulla P, Morelati F, Revelli N, Villa M, Paccapelo C, Nocco A. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol. 2004; 125 (1): 83-89.

  28. Kopko P, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune-refractory patients.Transfusion. 2015; 55 (2): 235-244. doi: 10.1111/trf.12921.

  29. Kalmadi S, Tiu R, Lowe C. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006; 107 (1): 136-140.

  30. Antun A, Gleason S, Arellano M. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013; 119 (21): 3784-3787.

  31. Ratko T, Burnett D, Foulke G. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA. 1995; 273 (23): 1865-1870.

  32. Schiffer C, Hogge D, Aisner J. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood. 1984; 64 (4): 937-940.

  33. Hogge D, Dutcher J, Aisner J. The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients. Blood. 1984; 64 (1): 253-256.

  34. Heddle N, Klama L, Kelton J. The use of anti-D to improve posttransfusion platelet response: a randomized trial. Br J Haematol. 1995; 89 (1): 163-168.

  35. Muñiz E, Martínez C, Madoz P. Refractariedad a las transfusiones de plaquetas. Med Clin. 2003; 120 (14): 544-549.

  36. Christie D, Howe R, Lennon S, Sauro S. Treatment of refractoriness to platelet transfusion by protein A column therapy. Trans. 1993; 33 (3): 234-242.

  37. Nagasawa T, Kim B, Baldini M. Temporary suppression of circulating antiplatelet alloantibodies by the massive infusion of fresh, stored, or lyophilized platelets. Trans. 1978; 18 (4): 429-435.

  38. Friedmann A, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002; 16 (1): 34-45.

  39. Lee E, Schiffer C. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusion in alloimmunized patients. Blood. 1987; 70 (6): 1727-1729.

  40. Narvios A, Reddy V, Martinez F. Slow infusion of platelets: a possible alternative in the management of refractory thrombocytopenic patients. Am J Hematol. 2005; 79 (1): 80.

  41. Heuer L, Blumenberg D. Management of bleeding in a multitransfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinol. 2005; 16 (4): 287-290.

  42. Vidarsson B, Onundarson P. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000; 83 (4): 634-635.




2020     |     www.medigraphic.com